Edition:
United States

Veru Inc (VERU.OQ)

VERU.OQ on NASDAQ Stock Exchange Capital Market

1.30USD
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
$1.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,919
52-wk High
$2.99
52-wk Low
$0.90

Latest Key Developments (Source: Significant Developments)

Veru Q1 Loss Per Share $0.08
Wednesday, 14 Feb 2018 06:30am EST 

Feb 14 (Reuters) - Veru Inc ::VERU REPORTS FISCAL 2018 FIRST-QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.08.Q1 REVENUE $2.6 MILLION VERSUS $3.2 MILLION.REMAIN ON TRACK TO FILE WITH FDA COMPANY'S FIRST NDA FOR TAMSULOSIN DRS IN 2018.PLAN TO SUBMIT TWO ADDITIONAL NDAS IN 2019.  Full Article

Veru Inc - On Jan 4, 2018, Daniel Haines, CFO, Informed Co That He Was Resigning ‍​
Wednesday, 10 Jan 2018 05:08pm EST 

Jan 10 (Reuters) - Veru Inc ::VERU INC - ON JAN 4, 2018, DANIEL HAINES, CFO, INFORMED CO THAT HE WAS RESIGNING ‍​.VERU SAYS ‍HAINES' DUTIES AS CFO WERE ASSIGNED EFFECTIVE JAN 4, 2018 TO MICHELE GRECO​ - SEC FILING.  Full Article

Veru reports Q4 Loss Per Share $0.10
Tuesday, 2 Jan 2018 07:00am EST 

Jan 2 (Reuters) - Veru Inc ::VERU REPORTS FISCAL 2017 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE $3.7 MILLION VERSUS $3.6 MILLION.  Full Article

Veru Acquires Novel Proprietary Formulation For Overactive Bladder
Monday, 11 Dec 2017 08:30am EST 

Dec 11 (Reuters) - Veru Inc ::VERU ACQUIRES NOVEL PROPRIETARY FORMULATION FOR OVERACTIVE BLADDER.VERU PLANS TO BEGIN SOLIFENACIN DRG BIOEQUIVALENCE STUDY IN 2018 AND TO FILE NDA IN 2019.‍UNDER TERMS OF AGREEMENT WITH CAMARGO, VERU PAID AN UNDISCLOSED UPFRONT FEE TO ACQUIRE ASSET​.UNDER TERMS, VERU TO PAY UNDISCLOSED MILESTONE FEES UPON SUCCESSFUL CLINICAL DEVELOPMENT, LOW SINGLE DIGIT ROYALTY UPON COMMERCIAL SALES​.FDA ‍CONFIRMED IN A MEETING WITH CO THAT REGULATORY APPROVAL FOR SOLIFENACIN DRG WILL REQUIRE A SINGLE BIOEQUIVALENCE STUDY​.  Full Article

Veru announces Tamsulosin drs bioequivalence clinical trial results
Monday, 13 Nov 2017 08:30am EST 

Nov 13 (Reuters) - Veru Inc :Veru announces Tamsulosin Drs bioequivalence clinical trial results.Veru Inc - ‍Expected timing of additional formulation adjustment should allow us to remain on track for a pre-NDA meeting in early 2018​.  Full Article

Veru files for mixed shelf of up to $50 million
Wednesday, 25 Oct 2017 05:49pm EDT 

Oct 25 (Reuters) - Veru Inc :Files for mixed shelf of up to $50 million - SEC filing‍​.  Full Article

Veru announces agreement with Timm Medical Technologies to distribute and to promote preboost
Tuesday, 3 Oct 2017 08:30am EDT 

Oct 3 (Reuters) - Veru Inc :Veru Inc announces agreement with Timm Medical Technologies LLC to distribute and to promote preboost.Veru Inc - signed United States distribution and co-promotion agreement with Timm Medical Technologies for preboost for prevention of premature ejaculation.Veru Inc - Veru grants Timm Medical Technologies distribution and promotion rights of preboost in United States and its territories.Veru Inc - Veru retains rights to also distribute and promote preboost sales in U.S..  Full Article

Veru reports Q3 loss per share $0.03
Tuesday, 8 Aug 2017 06:00am EDT 

Aug 8 (Reuters) - Veru Inc :Veru Inc reports fiscal third quarter financial results.Q3 loss per share $0.03.Qtrly unit sales totaled 8.5 million, which is 21 percent lower than 10.7 million from same prior-year quarter.Veru Inc qtrly net revenues $4.3 million versus $5.6 million.  Full Article

Veru Healthcare reports advancements in development of tamsulosin DRS for benign prostatic hyperplasia
Thursday, 20 Jul 2017 08:30am EDT 

July 20 (Reuters) - Female Health Co ::‍Veru Healthcare-initiated subject screening process for stage 2 of bioequivalence study of tamsulosin drs for treatment of benign prostatic hyperplasia​.‍Veru Healthcare - initiated manufacturing of nda required registration batch through its contract manufacturer, which will be used for FDA submission​.Veru Healthcare -manufacturing partner started production of commercial registration batch of tamsulosin drs.  Full Article

Veru Healthcare plans to advance its veru-944 into phase 2 clinical trial
Wednesday, 24 May 2017 08:30am EDT 

May 24 (Reuters) - Female Health Co : :Veru Healthcare - plans to advance its veru-944 into phase 2 clinical trial for treatment of hot flashes in men receiving hormone therapy for prostate cancer.Veru Healthcare -plan to commence phase 2 trial as soon as possible, and if successful, we expect to begin our phase 3 trial in second half of 2018.Veru Healthcare - decision to advance the drug followed a pre-investigational new drug application meeting with U.S. FDA.  Full Article

BRIEF-Veru Q1 Loss Per Share $0.08

* REMAIN ON TRACK TO FILE WITH FDA COMPANY'S FIRST NDA FOR TAMSULOSIN DRS IN 2018